|
Daily Medical Update
Avascular necrosis and osteonecrosis
Friday, July 31, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
The Journal of bone and joint surgery. American volume (2026) - Practice Guideline
Key Findings
- The ARCO panel agreed on 12 recommendations intended to improve diagnosis, evaluation, and management of nontraumatic ONFH.
- GRADE-based guidance is intended to reduce practice variation by standardizing staging, imaging selection, symptom attribution, and joint-preserving treatment decisions.
📋 Practice Implication: Use the ARCO guideline as the organizing framework for staging, imaging, and treatment selection in nontraumatic ONFH.
|
International orthopaedics (2026) - RCT
Key Findings
- At 24 months, ARCO stage II was maintained in 70% of lesion debridement with bone grafting patients versus 41% with core decompression.
- Lesion debridement with bone grafting reduced collapse risk versus core decompression with an NNT of 4, while serious adverse events were similar.
📋 Practice Implication: Favor lesion debridement with bone grafting over decompression alone for ARCO stage II glucocorticoid-associated ONFH when operative burden is acceptable.
|
Medical sciences (Basel, Switzerland) (2026) - Systematic Review
Key Findings
- MRI improved diagnostic certainty with pooled sensitivity of 0.91 and specificity of 0.96 for ONFH across included diagnostic studies.
- Core decompression plus bone marrow concentrate reduced femoral head collapse versus core decompression alone with pooled risk ratio 0.55.
📋 Practice Implication: Prioritize MRI for early diagnostic confirmation and consider biologically augmented decompression when counseling patients about joint preservation.
|
Frontiers in endocrinology (2026) - Systematic Review
Key Findings
- High-dose autologous stem cells combined with core decompression reduced conversion to total hip arthroplasty versus core decompression alone with odds ratio 0.24.
- High-dose stem cell augmentation also reduced femoral head collapse with odds ratio 0.24 and improved VAS pain scores.
📋 Practice Implication: When using stem cell augmentation, discuss high-dose protocols as the most promising option while noting uncertainty from heterogeneous dosing and follow-up.
|
Medical sciences (Basel, Switzerland) (2025) - Systematic Review
Key Findings
- Biological augmentation with core decompression improved Harris Hip Score and reduced VAS pain up to 24 months compared with core decompression alone.
- Radiologic progression and conversion to total hip arthroplasty were not significantly reduced, although long-term trends favored biologically augmented core decompression.
📋 Practice Implication: Set expectations that biologic augmentation mainly improves pain and function in early-stage disease, with less certain evidence for preventing structural progression.
|
|
💡
Summary
Recent high-significance evidence for avascular necrosis and osteonecrosis centers on nontraumatic osteonecrosis of the femoral head, where ARCO guidance reinforces standardized staging, MRI-based diagnosis, and selective joint-preserving intervention. Comparative and pooled data suggest stronger collapse prevention with bone grafting in stage II glucocorticoid-associated disease, while biologically augmented core decompression may improve pain and function and may reduce hip failure in selected early-stage patients.
|
|